CAJ | 학술논문

抗血管内皮生长因子(VEGF)药物治疗晚期肿瘤过程中所出现的耐药,可能与其他血管发生通路的激活、骨髓干细胞的动员、管周细胞及围管浸润的演变等相关.因此,探讨发生耐药的机制将有助于更深入了解正常组织、肿瘤及药物间的相互作用关系,并可能提示肿瘤治疗的新靶点.
항혈관내피생장인자(VEGF)약물치료만기종류과정중소출현적내약,가능여기타혈관발생통로적격활、골수간세포적동원、관주세포급위관침윤적연변등상관.인차,탐토발생내약적궤제장유조우경심입료해정상조직、종류급약물간적상호작용관계,병가능제시종류치료적신파점.
The resistance of anti-VEGF therapy which casually occurs during the course of tumor therapy by using anti-VEGF drugs may be associated with alternative angiogenesis signaling activation, bone marrowderived stem cells recruitment, pericyte coverage, perivascular invasion and so on. Thus, to investigate the mechanisms of drug resistance will guide us to understand deeply the relationship among normal tissues, tumors and drugs and to find out new therapeutic targets for anti-tumor therapy.